Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Fig. 2

The effect of MK-2206 on signaling in PBMC and PRP samples. Differences between baseline and post-treatment expression of pAKT-T308, pAKT-S473, pS6 S235/236 and pS6 S240/244 with two-sided t test. P < .05 was considered statistically significant. a Upper panel—platelets: group 1: early and C1D1: post-treatment, early and C1D2 for 15 patients who have early samples available. Group 2: C1D1:pre-treatment and C1D1: post-treatment, C1D1:pre-treatment and C1D2 for 13 patients who have C1D1:pre-treatment available. Lower panel—PBMC: group 1: early and C1D1:post-treatment, Early and C1D2 for 15 patients who have early samples available Group 2: C1D1:pre-treatment and C1D1:post-treatment, C1D1:pre-treatment and C1D2 for 13 patients who have C1D1:pre-treatment available. b Tumor

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us